ACADIA to Host Conference Call and Webcast on Monday, March 9, 2009, at 5:00 p.m. Eastern Time SAN DIEGO—(BUSINESS WIRE)—Mar. 2, 2009—ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical companyutilizing innovative technology to fuel drug discovery and clinicaldevelopment of novel treatments for central nervous system disorders,today announced that it will report its unaudited financial results forthe fourth quarter and year ended December 31, 2008 on Monday, March 9,2009, after the U.S. financial markets close. ACADIA's management willhost a conference call and webcast on Monday, March 9, 2009, at 5:00p.m. Eastern Time to discuss ACADIA’s financial results and developmentprograms.
The conference call may be accessed by dialing 866-700-0161 forparticipants in the U.S. or Canada and 617-213-8832 for internationalcallers (reference passcode 63914388). A telephone replay of theconference call may be accessed through March 23, 2009 by dialing888-286-8010 for callers in the U.S. or Canada and 617-801-6888 forinternational callers (reference passcode 11398116). The conference callalso will be webcast live on ACADIA’s website, www.acadia-pharm.com,under the investors section and will be archived there until March 23,2009.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology tofuel drug discovery and clinical development of novel treatments forcentral nervous system disorders. ACADIA is focused on developing aportfolio of its four most advanced product candidates, includingpimavanserin in Phase III for Parkinson’s disease psychosis, a productcandidate in Phase II for chronic pain and a product candidate in PhaseI for glaucoma, both in collaboration with Allergan, and ACP-106 inIND-track development. All of the product candidates in ACADIA’spipeline emanate from discoveries made using its proprietary drugdiscovery platform. ACADIA maintains a website at www.acadia-pharm.comto which ACADIA regularly posts copies of its press releases as well asadditional information and through which interested parties cansubscribe to receive email alerts.
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director,Investor Relations
Thomas H. Aasen, Vice President and ChiefFinancial Officer
858-558-2871